Follicle Pharma

Company Overview

Snapshot

Founded in March 2018 by Masanobu Ogawa, Doron Friedman, and Eran Perry, Follicle Pharma operates with 1–10 employees. The company has raised $5 million across one funding round. In January 2021, Follicle Pharma secured seed funding from Maruho Israel Innovation Fund.

Business overview

Follicle Pharma is a Health Tech & Life Sciences company focused on advancing treatments for follicular diseases. The company develops a new class of topical targeted delivery systems designed to overcome the unique challenges of intra-folfollicular delivery. Its technology platform and intellectual property are based on research into particle behavior in emulsions and hydrophobic active ingredients, allowing for tailored compositions and processes for various active pharmaceutical ingredients. Follicle Pharma operates within the Pharmaceuticals sector, serving the Healthcare & Life Sciences market with products like FOL100 and FOL500, which are currently in clinical trials.

Company Intelligence Q&A

When was Follicle Pharma founded?

Follicle Pharma was founded in March 2018 by Masanobu Ogawa, Doron Friedman, and Eran Perry.

What is Follicle Pharma's primary focus?

Follicle Pharma focuses on developing hair follicle-targeted therapeutics, specifically new topical delivery systems for follicular diseases.

What is the status of Follicle Pharma's products?

Follicle Pharma's products, including FOL100 and FOL500, are currently in the clinical trial stage.

What is Follicle Pharma's core technology?

Follicle Pharma's core technology platform and intellectual property are based on the research of particle behavior in emulsions and hydrophobic active ingredients, enabling tailored compositions for intra-follicular delivery.

Which investor participated in Follicle Pharma's seed funding round?

In January 2021, Follicle Pharma secured seed funding from Maruho Israel Innovation Fund.